GlassScriptPhysician profile
Thomas James Benda
NPI 1003897554
$875.35
in general payments reported to CMS, 2019-2025
17 companies · $27.71 in 2025
The $27.71 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $81.49 · 2021: $177 · 2022: $53.11 · 2023: $30.45 · 2024: $97.59 · 2025: $27.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $140.90 | 2019-2022 | |
| Alk-Abello, INC | $89.75 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $83.22 | 2019 | |
| Arrinex, INC. | $73.33 | 2019 | |
| Smith+Nephew, INC. | $72.45 | 2020-2024 | Tula, Coblation |
| Aerin Medical INC. | $64.71 | 2019-2020 | |
| Convatec INC. | $56.55 | 2024 | |
| Optinose US, INC. | $50.60 | 2019-2020 | |
| Intersect Ent, INC. | $43.53 | 2019-2021 | |
| Acclarent, INC | $39.38 | 2021 | |
| Genzyme Corporation | $36.90 | 2021-2023 | |
| Karl Storz Endoscopy-America | $32.57 | 2019 | |
| Neurent Medical Limited | $27.71 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Medtronic, INC. | $22.21 | 2021 | |
| Integra Lifesciences Corporation | $16.46 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.05 | 2023 | Nucala |
| Covidien LP | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Benda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.